Classical swine fever (CSF) is a contagious, often fatal, disease affecting both feral and domesticated pigs. Outbreaks in Europe, Asia, Africa, and South America have not only adversely impacted animal health and food security but have also had severe socio-economic impacts on both the pig industry worldwide and small-scale pig farming.
In collaboration with the Institute of Infectious Animal Diseases (IIAD) at Texas A&M University and Kansas State University, iBio used the FastPharming system to develop a potentially safe and protective (DIVA)-capable subunit vaccine.1 Formulated in cost-effective oil-in-water emulsion adjuvants, IBIO-400 studies have shown that after single-dose vaccination, the adjuvanted, plant-made CSF E2 subunit vaccine provides complete protection in challenged pigs and is accompanied by strong virus neutralization antibody responses.
Producing a subunit vaccine in plants saves time and money
Studies showed protection after a single dose
All vaccinated animals were protected from CSF clinical signs
Provided through the absence of Ems response
Potential for use in bait for feral hogs (natural virus reservoirs) without substantial purification, unlike live attenuated vaccines
Possible rapid adaptation to regional strain variations and emerging novel subgenotypes
IBIO-400 demonstrated a robust immune response associated with full protection in swine during a challenge study. The vaccine also provided complete protection in challenged pigs after a single-dose vaccination, which was accompanied by strong virus neutralization antibody responses.